Preview Mode Links will not work in preview mode

Nov 23, 2020

Featuring a roundtable discussion with Drs Scott Kopetz, Wells A Messersmith and Alan P Venook on the following topics:

  • Biomarkers in Metastatic Colorectal Cancer (mCRC)
    • Case: A man in his mid-20s with microsatellite instability (MSI)-high metastatic adenocarcinoma of the colon and ROS1 deletion experiences a complete response with ceritinib on a clinical trial — Wells A Messersmith, MD (0:00)
    • Assessment of biomarkers for patients with mCRC (6:51)
    • Role of repeat biopsy and liquid biopsies for patients with progressive mCRC (10:12)
  • Current and Emerging Role of Immune Checkpoint Inhibitors in the Management of mCRC
    • Incidence of high MSI among patients with localized and metastatic CRC; MSI testing and implications for the diagnosis of Lynch syndrome (12:26)
    • Case: A man in his mid-80s with a history of diffuse non-Hodgkin lymphoma is diagnosed with MSI-high mCRC and receives nivolumab — Scott Kopetz, MD, PhD (14:35)
    • Predictors of benefit from immune checkpoint inhibitors in patients with MSI-high CRC; role of tumor mutation burden in response to immunotherapy (18:15)
    • Duration of treatment with immune checkpoint inhibitors; dosing schedule for pembrolizumab in the era of the COVID-19 pandemic (23:17)
    • Case: A man in his early 40s with MSI-high CRC and multiple liver metastases — Alan P Venook, MD (26:35)
    • Efficacy and tolerability of immune checkpoint inhibitors alone or in combination as first-line therapy for patients with MSI-high mCRC (31:17)
    • Choice of chemotherapy regimen in the first-line setting for patients with left-sided MSI-high mCRC (37:36)
    • Results from the KEYNOTE-177 study evaluating first-line pembrolizumab versus investigator’s choice of chemotherapy for MSI-high/mismatch repair-deficient mCRC (48:00)
  • Expanding Therapeutic Options for Patients with mCRC with BRAF V600E Mutations
    • Case: A woman in her mid-70s with MSI-high mCRC and a BRAF V600E mutation experiences a dramatic response to first-line nivolumab — Dr Messersmith (51:40)
    • Case: A man in his early 60s with mCRC and a BRAF V600E mutation receives encorafenib and cetuximab on the BEACON CRC study — Dr Kopetz (55:28)
    • Biology and management of mCRC with BRAF mutation (1:00:30)
    • Case: A man in his early 70s with right-sided mCRC and a BRAF V600E mutation attains an excellent response to the combination of encorafenib, binimetinib and panitumumab — Dr Venook (1:04:15)
    • Case: A woman in her late 40s with mCRC and a BRAF V600E mutation receives encorafenib with panitumumab after disease progression on chemotherapy/bevacizumab — Dr Messersmith (1:12:00)
    • Case: A woman in her late 30s with microsatellite-stable mCRC and a BRAF V600E mutation — Dr Venook (1:15:52)
    • Novel strategies under investigation for the treatment of mCRC with a BRAF mutation (1:18:33)
    • Sequencing therapies for patients with mCRC and BRAF mutations (1:22:20)
    • BEACON CRC trial: Efficacy and safety of encorafenib in combination with cetuximab and binimetinib for mCRC with a BRAF V600E mutation (1:24:42)
  • HER2 and Other Emerging Biomarkers in mCRC
    • Case: A woman in her early 50s with HER2-amplified CRC and lung metastases receives trastuzumab deruxtecan (DS-8201a) on a clinical trial — Dr Kopetz (1:28:15)
    • Activity and tolerability of the novel anti-HER2 antibody-drug conjugate trastuzumab deruxtecan in patients with advanced CRC (1:33:03)
  • Impact of Tumor Location on First-Line Treatment; Selection of Biologic Agent
    • Therapeutic approach to left-sided pan-RAS wild-type CRC (1:36:38)
    • Quality of life and dermatologic toxicities with EGFR inhibitor therapy; association of skin rash with outcomes (1:41:06)
    • Myths and misconceptions in the management of CRC (1:43:52)

CME information and select publications